参考文献/References:
[1] Haanen JBAG,Carbonnel F,Robert C,et al.Management of toxicities from immunotherapy:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2017,28(suppl_4):iv119-iv142.DOI:10.1093/annonc/mdx225.
[2] Chang LS,Barroso-Sousa R,Tolaney SM,et al.Endocrine Toxicity of cancer immunotherapy targeting Immune checkpoints[J].Endocr Rev,2019,40(1):17-65.DOI:10.1210/er.2018-00006.
[3] Stamatouli AM,Quandt Z,Perdigoto AL,et al.Collateral damage:Insulin-Dependent diabetes induced with checkpoint inhibitors[J].Diabetes,2018,67(8):1471-1480.DOI:10.2337/dbi18-0002.
[4] Cukier P,Santini FC,Scaranti M,et al.Endocrine side effects of cancer immunotherapy[J].Endocr Relat Cancer,2017,24(12):331-347.DOI:10.1530/ERC-17-0358.
[5] Lopes AR,Russo A,Li AY,et al.Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab:a case report[J].Transl Lung Cancer Res,2020,9(5):2149-2156.DOI:10.21037/tlcr-20-408.
[6] 中华医学会内分泌学分会免疫内分泌学组.免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)[J].中华内分泌代谢杂志,2021,37(01):1-16.DOI:10.3760/cma.j.cn311282-20200627-00475.
[7] de Filette JMK,Pen JJ,Decoster L,et al.Immune checkpoint inhibitors and type 1 diabetes mellitus:a case report and systematic review[J].Eur J Endocrinol,2019,181(3):363-374.DOI:10.1530/EJE-19-0291.
[8] Clotman K,Janssens K,Specenier P,et al.Programmed cell Death-1 Inhibitor-Induced type 1 diabetes mellitus[J].J Clin Endocrinol Metab,2018,103(9):3144-3154.DOI:10.1210/jc.2018-00728.
[9] Marchand L,Thivolet A,Dalle S,et al.Diabetes mellitus induced by PD-1 and PD-L1 inhibitors:description of pancreatic endocrine and exocrine phenotype[J].Acta Diabetol,2019,56(4):441-448.DOI:10.1007/s00592-018-1234-8.
[10] Ansari MJ,Salama AD,Chitnis T,et al.The programmed death-1(PD-1)pathway regulates autoimmune diabetes in nonobese diabetic(NOD)mice[J].J Exp Med,2003,198(1):63-69.DOI:10.1084/jem.20022125.
[11] Kotwal A,Haddox C,Block M,et al.Immune checkpoint inhibitors:an emerging cause of insulin-dependent diabetes[J].BMJ Open Diabetes Res Care,2019,7(1):e000591.DOI:10.1136/bmjdrc-2018-000591.
[12] Ishikawa K,Shono-Saito T,Yamate T,et al.A case of fulminant type 1 diabetes mellitus,with a precipitous decrease in pancreatic volume,induced by nivolumab for malignant melanoma:analysis of HLA and CTLA-4 polymorphisms[J].Eur J Dermatol,2017,27(2):184-185.DOI:10.1684/ejd.2016.2923.
[13] Patel S,Chin V,Greenfield JR.Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism[J].Endocrinol Diabetes Metab Case Rep,2019,2019:19-0098.DOI:10.1530/EDM-19-0098.
[14] Mengíbar JL,Capel I,Bonfill T,et al.Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment[J].Endocrinol Diabetes Metab Case Rep,2019,2019(1):19-0045.DOI:10.1530/EDM-19-0045.
[15] Way J,Drakaki A,Drexler A,et al.Anti-PD-L1 therapy and the onset of diabetes mellitus with positive pancreatic autoantibodies[J].BMJ Case Rep,2017,2017:bcr2017220415.DOI:10.1136/bcr-2017-220415.
[16] Brahmer JR,Lacchetti C,Schneider BJ,et al.Management of Immune-Related adverse events in patients treated with immune checkpoint inhibitor therapy:American Society of Clinical Oncology Clinical Practice Guideline[J].J Clin Oncol,2018,36(17):1714-1768.DOI:10.1200/JCO.2017.77.6385.
[17] Aleksova J,Lau PK,Soldatos G,et al.Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma[J].BMJ Case Rep,2016,2016:bcr2016217454.DOI:10.1136/bcr-2016-217454.
[18] Chae YK,Chiec L,Mohindra N,et al.A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes[J].Cancer Immunol Immunother,2017,66(1):25-32.DOI:10.1007/s00262-016-1913-7.
[19] Trinh B,Donath MY,Läubli H.Successful treatment of immune checkpoint Inhibitor-Induced diabetes with infliximab[J].Diabetes Care,2019,42(9):e153-e154.DOI:10.2337/dc19-0908.